# The Race to Salvage Glucocerebrosidase: Understanding Small‐Molecule Therapies for GBA1 ‐Associated Parkinsonism

## TL;DR

This paper explores small-molecule therapies that improve glucocerebrosidase function to treat Parkinsonism linked to GBA1 gene variants.

## Contribution

The paper provides insights into the mechanism of small molecules that enhance glucocerebrosidase activity for Parkinson's treatment.

## Key findings

- GBA1 gene variants are linked to both Gaucher disease and increased Parkinsonism risk.
- Small molecules can improve glucocerebrosidase function in lysosomes.
- Understanding these mechanisms could lead to new therapies for Parkinson's disease.

## Abstract

Variants in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, cause Gaucher disease and confer an increased risk for parkinsonism. Strategies using small molecules can improve the function of glucocerebrosidase in lysosomes. A clear understanding of the mechanism‐of‐action of these compounds will facilitate development of GBA1‐modulating drugs for Parkinson's disease.